Finelli A - Search Results

1

Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe.

Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A. Richard PO, et al. Among authors: finelli a. J Urol. 2016 Mar;195(3):581-6. doi: 10.1016/j.juro.2015.09.067. Epub 2015 Sep 24. J Urol. 2016. PMID: 26388501

2

Cryotherapy and radiofrequency ablation: pathophysiologic basis and laboratory studies.

Finelli A, Rewcastle JC, Jewett MA. Finelli A, et al. Curr Opin Urol. 2003 May;13(3):187-91. doi: 10.1097/00042307-200305000-00003. Curr Opin Urol. 2003. PMID: 12692439 Review.

3

Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma.

Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC. Rabets JC, et al. Among authors: finelli a. Urology. 2004 Nov;64(5):930-4. doi: 10.1016/j.urology.2004.06.052. Urology. 2004. PMID: 15533480

4

Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors.

Steinberg AP, Finelli A, Desai MM, Abreu SC, Ramani AP, Spaliviero M, Rybicki L, Kaouk J, Novick AC, Gill IS. Steinberg AP, et al. Among authors: finelli a. J Urol. 2004 Dec;172(6 Pt 1):2172-6. doi: 10.1097/01.ju.0000140961.53335.04. J Urol. 2004. PMID: 15538225

5

Evidence for a biopsy derived grade artifact among larger prostate glands.

Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: finelli a. J Urol. 2006 Feb;175(2):505-9. doi: 10.1016/S0022-5347(05)00236-3. J Urol. 2006. PMID: 16406982

6

An efficient solution to the retained Foley catheter.

Hamilton RJ, Jewett MA, Finelli A. Hamilton RJ, et al. Among authors: finelli a. Urology. 2006 Nov;68(5):1109-11. doi: 10.1016/j.urology.2006.06.012. Urology. 2006. PMID: 17113905

7

Expanding the indications for laparoscopic radical nephrectomy.

Mattar K, Finelli A. Mattar K, et al. Among authors: finelli a. Curr Opin Urol. 2007 Mar;17(2):88-92. doi: 10.1097/MOU.0b013e32802b7070. Curr Opin Urol. 2007. PMID: 17285016 Review.

8

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: finelli a. Cancer. 2007 Jun 15;109(12):2432-8. doi: 10.1002/cncr.22712. Cancer. 2007. PMID: 17497649 Free article.

9

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R; REDEEM Study Group. Fleshner N, et al. Among authors: finelli a. Contemp Clin Trials. 2007 Nov;28(6):763-9. doi: 10.1016/j.cct.2007.05.006. Epub 2007 May 29. Contemp Clin Trials. 2007. PMID: 17573244

10

Optimal management of high-risk T1G3 bladder cancer: a decision analysis.

Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Kulkarni GS, et al. Among authors: finelli a. PLoS Med. 2007 Sep;4(9):e284. doi: 10.1371/journal.pmed.0040284. PLoS Med. 2007. PMID: 17896857 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters